Intellia Therapeutics, Inc.
NTLA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $13,782 | $14,245 | $16,627 | $12,874 |
| % Growth | -3.3% | -14.3% | 29.2% | – |
| Cost of Goods Sold | $78,949 | $0 | $0 | $0 |
| Gross Profit | -$65,167 | $14,245 | $16,627 | $12,874 |
| % Margin | -472.8% | 100% | 100% | 100% |
| R&D Expenses | $94,747 | $97,035 | $108,427 | $116,877 |
| G&A Expenses | $30,512 | $27,206 | $29,007 | $32,444 |
| SG&A Expenses | $46,310 | $27,206 | $29,007 | $32,444 |
| Sales & Mktg Exp. | $15,798 | $0 | $0 | $0 |
| Other Operating Expenses | -$94,747 | $0 | $0 | $0 |
| Operating Expenses | $46,310 | $124,241 | $137,434 | $149,321 |
| Operating Income | -$111,477 | -$109,996 | -$120,807 | -$136,447 |
| % Margin | -808.9% | -772.2% | -726.6% | -1,059.9% |
| Other Income/Exp. Net | $10,153 | $8,741 | $6,478 | $7,549 |
| Pre-Tax Income | -$101,324 | -$101,255 | -$114,329 | -$128,898 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$101,324 | -$101,255 | -$114,329 | -$128,898 |
| % Margin | -735.2% | -710.8% | -687.6% | -1,001.2% |
| EPS | -0.92 | -0.98 | -1.1 | -1.27 |
| % Growth | 6.1% | 10.9% | 13.4% | – |
| EPS Diluted | -0.92 | -0.98 | -1.1 | -1.27 |
| Weighted Avg Shares Out | 110,188 | 103,732 | 103,500 | 101,855 |
| Weighted Avg Shares Out Dil | 110,188 | 103,732 | 103,500 | 101,855 |
| Supplemental Information | – | – | – | – |
| Interest Income | $6,714 | $7,402 | $8,603 | $10,631 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $4,936 | $2,474 | $2,498 | $2,566 |
| EBITDA | -$96,388 | -$107,522 | -$118,309 | -$133,881 |
| % Margin | -699.4% | -754.8% | -711.5% | -1,039.9% |